Breast Cancer,HER2+ Comparing Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Metastatic Breast Cancer Phase 3 Trial Feb 24, 2023
Breast Cancer,HER2+ Adjuvant T-DM1 vs. Trastuzumab in Residual HER2+ Breast Cancer: KATHERINE Phase 3 Results Feb 24, 2023
Breast Cancer,HER2- Neoadjuvant Evaluation of Ganetespib in Stage II/III Breast Cancer Treatment Feb 09, 2023
Breast Cancer,HER2- Phase 3 Trial Analysis on HER2-Negative, Node-Positive Early Breast Cancer With Abemaciclib Plus Endocrine Therapy Effective Feb 09, 2023
